ConferenceDiabetes · June 5, 2026
Introduction and Objective: Screening for metabolic dysfunction-associated steatohepatitis (MASH) in type 2 diabetes (T2D) is recommended by multiple society guidelines. Guideline-based MASH care pathways can be operationalized in the electronic he ...
Full textCite
ConferenceDiabetes · June 5, 2026
Introduction and Objective: BMI-based criteria may not be sufficiently sensitive to identify people at-risk of poor cardiometabolic outcomes. We evaluated whether multi-organ imaging could improve prediction of obesity-related health outcomes and i ...
Full textCite
ConferenceGastro Hep Adv · 2024
BACKGROUND AND AIMS: We aimed to test the performance of the Fibroscan-aspartate aminotransferase (FAST) score, a noninvasive test, to identify nonalcoholic steatohepatitis (NASH) and significant fibrosis (NASH + ≥F2) in a cohort of patients with a histolo ...
Full textLink to itemCite
ConferenceJ Gastrointest Cancer · March 2012
BACKGROUND: Gastric cancer remains a major public health issue and is a leading cause of death worldwide, accounting for 600,000 deaths annually. Over the last decades, there has been a steady decline in the incidence rates of gastric cancer. Furthermore, ...
Full textLink to itemCite
